兰德-英国癌症研究更具弹性的资金选择评估（英）

More resilient funding for cancer research in the UK An option appraisalHampton Toole, Jon Sussex, Mehdi Shiva, Sorana Bucseneanu, Mark Cabling, Priyanka Cardoz, Shaun LeamonFor more information on this publication, visit www.rand.org/t/RRA3895-1About RAND Europe RAND Europe is a not-for-profit research organisation that helps improve policy and decision making through research and analysis. To learn more about RAND Europe, visit www.randeurope.org.Research Integrity Our mission to help improve policy and decision making through research and analysis is enabled through our core values of quality and objectivity and our unwavering commitment to the highest level of integrity and ethical behaviour. To help ensure our research and analysis are rigorous, objective, and nonpartisan, we subject our research publications to a robust and exacting quality-assurance process; avoid both the appearance and reality of financial and other conflicts of interest through staff training, project screening, and a policy of mandatory disclosure; and pursue transparency in our research engagements through our commitment to the open publication of our research findings and recommendations, disclosure of the source of funding of published research, and policies to ensure intellectual independence. For more information, visit www.rand.org/about/research-integrity.© 2025 Cancer Research UKAll rights reserved. No part of this book may be reproduced in any form by any electronic or mechanical means (including photocopying, recording, or information storage and retrieval) without permission in writing from Cancer Research UK.RAND’s publications do not necessarily reflect the opinions of its research clients and sponsors.Published by the RAND Corporation, Santa Monica, Calif., and Cambridge, UKR® is a registered trademark.Cover: AntonKhrupinArt, Adobe StockiNon-commercial cancer research in the UK relies heavily on the charity sector for funding, which in turn is substantially reliant on income from donations. This status quo can create challenges for predictably funding cancer research in the UK, requiring further thinking on how to make the funding model more resilient. That is the key question which this report addresses. This work was funded by Cancer Research UK and carried out by researchers at RAND Europe. PrefaceiiMore resilient funding for cancer research in the UK: An option appraisalSummary Context and rationale for the studyRelative to the size of its economy, the UK contributes a large proportion of the worldwide medical research effort, including cancer research. This not only helps prevent and treat cancer in the UK and worldwide but also strengthens the UK economy by making it a competitive location for research, generating jobs and income. Maintaining that strong position requires a sustained commitment to cancer research funding over time.According to the latest figures available, non- and pre-commercial medical research (not just cancer research) received